Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$0.70 target price on Theralase (Theralase Technologies Stock Quote, Chart, News, Analysts, Financials TSXV:TLT) in a Jan. 12 update following the company’s announcement of a new clinical collaboration with Ferring Pharmaceuticals. Theralase said it has entered into a collaborative clinical development agreement with Ferring […]
Stifel Canada resumed coverage of HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:HLS) with a “Hold” rating and raised its target price to $4.75 from $4.00, reflecting the inclusion of newly licensed cardiovascular drug Nilemdo in its valuation framework. In a company update, Stifel analyst Justin Keywood said recent discussions with management […]
Share
Tweet
Share
